Table 5 Head to head relative treatment effects expressed as odds ratios (mean, 95% CrI)

CCyR (6 months)

Dasatinib 100 mg

N/A

0.76 (0.1, 9.31)

0.91 (0.12, 10.58)

Nilotinib 600 mg

1.32 (0.11, 9.58)

N/A

1.2 (0.23, 5.5)

Nilotinib 800 mg

1.10 (0.09, 8.29)

0.84 (0.18, 4.27)

N/A

CCyR (12 months)

Dasatinib 100 mg

N/A

0.95 (0.41, 2.22)

1.09 (0.47, 2.60)

Nilotinib 600 mg

1.05 (0.45, 2.43)

N/A

1.15 (0.58, 2.32)

Nilotinib 800 mg

0.92 (0.38, 2.13)

0.87 (0.43, 1.73)

N/A

CCyR (18 months)

Dasatinib 100 mg

N/A

0.77 (0.44, 1.36)

0.95 (0.54, 1.66)

Nilotinib 600 mg

1.30 (0.73, 2.29)

N/A

1.23 (0.79, 1.92)

Nilotinib 800 mg

1.05 (0.60, 1.84)

0.81 (0.52, 1.27)

N/A

MMolR (12 months)

Dasatinib 100 mg

N/A

0.74 (0.45, 1.19)

0.76 (0.47, 1.22)

Nilotinib 600 mg

1.35 (0.84, 2.20)

N/A

1.04 (0.74, 1.45)

Nilotinib 800 mg

1.31 (0.82, 2.13)

0.96 (0.69, 1.35)

N/A